uniQure to Announce 2025 Financial Results
uniQure (NASDAQ: QURE) will report fourth-quarter and full-year 2025 financial results before market open on Monday, March 2, 2026.
Rhea-AI Summary
uniQure (NASDAQ: QURE) will report fourth-quarter and full-year 2025 financial results before market open on Monday, March 2, 2026. Management will host a live conference call at 8:00 a.m. ET the same day.
The event will be webcast via the company’s Events & Presentations page and a replay will be archived for 90 days. Analysts may join the live Q&A by phone using conference ID 4607289; attendees are asked to dial in 15 minutes early.
Positive
- None.
Negative
- None.
Details
News Market Reaction – QURE
In the Feb 23 session, QURE gained 4.42%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Earnings date
- March 2, 2026
- Q4 and full-year 2025 results to be reported before market open
- Earnings call time
- 8:00 a.m. ET
- Conference call on March 2, 2026
- Replay period
- 90 days
- Webcast replay availability after earnings call
- Conference ID
- 4607289
- ID for analysts joining the live Q&A
- Join early window
- 15 minutes
- Requested arrival before call start time
- Current price
- $23.43
- Pre-news close relative to upcoming earnings-date announcement
- 52-week range
- $7.76–$71.50
- Shares <b>-67.23%</b> vs high, <b>201.93%</b> vs low pre-announcement
- Market cap
- $1,519,916,577
- Equity value before Q4 and full-year 2025 earnings release
Previous Earnings date Reports
-
Set timing for Q3 2025 results and investor conference call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
~ uniQure to host earnings call on Monday, March 2, 2026 at 8:00 a.m. ET ~
LEXINGTON, Mass. and AMSTERDAM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report fourth quarter and full year of 2025 financial results before market open on Monday, March 2, 2026. Management will then host a conference call at 8:00 a.m. ET.
The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 or toll-free (800) 715-9871 and entering conference ID 4607289. If you are joining the conference call, please join 15 minutes before the start time.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases. www.uniQure.com
uniQure Contacts:
| FOR INVESTORS: | FOR MEDIA: |
| Chiara Russo | Tom Malone |
| Direct: 781-491-4371 | Direct: 339-970-7558 |
| Mobile: 617-306-9137 | Mobile:339-223-8541 |
| c.russo@uniQure.com | t.malone@uniQure.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.